Free shipping over €200 | Certificate of Analysis included | ✉️ support@certapeptides.com | 💬 Live Chat
Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.

Delivers to EU in 7-10 business days
Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
Research-grade Oral BPC-157 + TB-500 Blend. 99.3% avg purity, HPLC & MS verified. Oral tablets in sealed bottle. For laboratory research use only. Not for human consumption.
MADE TO ORDER — Expected delivery: ~3 weeks
Synthesized after your order is placed. We'll email you tracking details when it ships.
This product is being restocked
We're working with our supplier to restock this item. Sign up below to be the first to know, or save it to your wishlist.
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
99.3% average HPLC purity, verified by independent third-party testing
Janoshik report published when available
24h dispatch, EU-wide shipping from €4.99
Independent lab verification for every batch
Oral BPC-157 + TB-500 Blend combines 500mcg each of BPC-157 and TB-500 in a single capsule. The combination pairs BPC-157's well-documented gastric acid stability with TB-500's actin-modulating tissue biology, making it useful for researchers studying oral peptide delivery alongside the potential for complementary tissue remodeling mechanisms in GI tissue models.
BPC-157 and TB-500 have been studied independently for overlapping but distinct properties: BPC-157 primarily through nitric oxide pathway modulation and mucosal cytoprotection; TB-500 through actin dynamics, cell migration, and angiogenesis. Both have published preclinical work in tissue remodeling contexts, and there are proposed mechanistic interactions. Whether oral co-administration produces additive, synergistic, or simply independent effects is the kind of question this blend is designed to help researchers address. The format is straightforward -- one capsule for researchers who want to study both peptides as a combined oral intervention.
One practical consideration: BPC-157's gastric acid stability means it survives to reach intestinal tissue, while TB-500's GI survival is less certain. This means the blend may effectively deliver primarily BPC-157 to GI tissue, with TB-500's contribution depending on formulation protection. Research designs using this blend should account for this asymmetry in oral bioavailability between the two components.
Useful for combination therapy research in tissue remodeling models, comparative studies of individual versus combined peptide administration via oral route, and investigation of mechanistic interactions between nitric oxide signaling (BPC-157) and actin cytoskeleton dynamics (TB-500) in GI and healing contexts.
| Parameter | Value |
|---|---|
| Component 1 | BPC-157 500mcg (CAS 137525-51-0) |
| Component 2 | TB-500 500mcg (Thymosin Beta-4 fragment) |
| Total Dose | 1,000mcg combined per capsule |
| Purity | 99.3% avg HPLC (each component) |
| Format | Oral capsule, lyophilized fill |
| Storage | Room temperature or refrigerate for extended stability |
Store at room temperature in a cool, dry place; refrigerate for longer-term stability. Keep dry and away from heat sources. The capsule fill is lyophilized, providing better stability than reconstituted solutions.
Some combination studies suggest additive or enhanced effects when both are administered together, but the mechanistic basis is not fully characterized. BPC-157 primarily modulates the nitric oxide system and mucosal tissue pathways; TB-500 acts through actin cytoskeleton dynamics and cell migration. These pathways are distinct but tissue remodeling involves both cellular motility (TB-500 territory) and vascular support plus mucosal protection (BPC-157 territory). Whether the combination produces meaningfully different results than either alone in an oral format is exactly the research question this blend is designed to investigate.
BPC-157 has documented stability in gastric acid conditions, consistent with its origin from gastric juice. TB-500 does not have this documented stability, so its GI survival is more uncertain and dependent on capsule encapsulation providing protection. This means the two components may have different effective doses reaching intestinal tissue -- a variable that researchers should factor into study design and data interpretation when using this blend.
The blend simplifies protocol design for researchers who want to administer both peptides simultaneously -- one capsule instead of two separate administrations. For combination therapy research where the interaction between the two peptides is the primary interest, co-formulation also ensures they are delivered at the same time and dose ratio in every subject. For dose-ranging experiments or protocols where individual components need independent control, separate products provide more flexibility.
Oral BPC-157 + TB-500 Blend is supplied for laboratory research use only. Not approved for human use. Handle in compliance with institutional biosafety guidelines.
Researcher Confidence
Who actually tests this?
Every batch is independently verified by Janoshik Analytical (100,000+ verifications/month), Eurofins Scientific, and Analytical Sciences International. We publish every Certificate of Analysis.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI RO54451735, VAT-registered. SameDay for Romania, FanCourier for Central/Eastern EU, TCE Worldwide for the rest. 3–7 business days EU-wide.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
500mcgSAME FIELDResearch-grade Oral TB-500. 99.3% avg purity, HPLC & MS verified. Oral tablets in sealed bottle. For laboratory research use only. Not for human consumption.
500mcgSAME FIELDEnteric-coated oral BPC-157 capsules. 60 capsules per bottle, 500mcg BPC-157 per capsule (30g total per bottle). 99.3% avg HPLC purity, independent COA per batch. Supplied for in vitro research into oral peptide bioavailability and intestinal tissue protection. EU-wide 3–7 day shipping.
2mgSAME FIELDResearch-grade IGF-DES. 99.3% avg purity, HPLC & MS verified. Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
SAME FIELDIGF-1 LR3 (Long Arg3 IGF-1) is an 83-amino acid analog of insulin-like growth factor 1 with an arginine substitution at position 3 and a 13-amino acid N-terminal extension. These modifications significantly reduce IGF binding protein affinity, increasing bioavailability in research applications. Extended analog of IGF-1 with enhanced bioavailability Muscle hypertrophy and tissue growth studies IGF-1 signaling pathway and receptor activation research For research purposes only.